Stevanato Group SpA

We initiated positions in Stevanato Group (STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology, and life sciences industries. The stock sold off following the launch of oral GLP-1s, which many believe will end the need for injectable forms. However, experts believe an expanding GLP-1 TAM, coupled with varying use cases, will necessitate ongoing need for injectable forms. This market overreaction offered an attractive entry valuation of 12.5x FY2026E EBITDA vs. STVN’s historic multiple of 20X and its nearest comp West Pharmaceutical (WST) at approximately 22–25x.

Stevanato Group has evolved into a vertically integrated, mission-critical supplier serving customers in over 70 countries. The company has made a strategic shift to focus on High-Value Solutions, including premium products like Nexa® high-performance prefilled syringes and EZ-fill® vials designed for biologics. This strategic focus has enabled an inflection in revenue growth, margin expansion, and free cash flow generation, reinforcing our confidence in the franchise's durability.

Stevanato (STVN) is mentioned as a pharmaceutical glass manufacturer that is on the cusp of completing multi-year capacity expansions and is expected to inject positive cash flows. However, there is no explicit bullish or bearish argument presented regarding its future performance or valuation.

Stevanato Group SpA (STVN) was the largest detractor in the quarter as investors weighed solid results against a mixed underlying business mix, modest revenue growth, and a moderating earnings growth profile. The stock struggled despite improvements in margins and high-value solutions scaling, with overall revenue growth remaining relatively modest at 5% in the quarter. Continued weakness in the Engineering segment and a transition toward higher-value products contributed to a more tempered market reaction.